Zobrazeno 1 - 10
of 644
pro vyhledávání: '"Antiresorptives"'
Autor:
Aleksandra Dziewulska, Weronika Kiełt, Julia Kozłowska, Gabriela Broniec, Barbara Wajdowicz, Aleksandra Kudła, Rozalia Czapiewska, Aleksandra Wróbel, Laura Pacek, Klaudia Kowalska
Publikováno v:
Journal of Education, Health and Sport, Vol 69 (2024)
Introduction: Antiresorptive drugs such as bisphosphonates and denosumab are crucial for treating osteoporosis, metastatic bone disease, and hypercalcemia by inhibiting osteoclast function. They can lead to medication-related osteonecrosis of the jaw
Externí odkaz:
https://doaj.org/article/a46ce4a832ce43f3a439421d7e3cfd4b
Autor:
Qihua Tan, Anaïs Marie Julie Møller, Chuan Qiu, Jonna Skov Madsen, Hui Shen, Troels Bechmann, Jean-Marie Delaisse, Bjarne Winther Kristensen, Hong-Wen Deng, David Karasik, Kent Søe
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-14 (2023)
Abstract Background Clinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients. Human osteoclasts ex vivo reportedly displayed a variable sensitivity to zoledronic acid > 2
Externí odkaz:
https://doaj.org/article/9718cb5c044c48b18465cf4ae6ccc452
Autor:
Leslie Spangler, Carrie M. Nielson, M. Alan Brookhart, Rohini K. Hernandez, Robert Kees Stad, Tzu‐Chieh Lin
Publikováno v:
JBMR Plus, Vol 7, Iss 10, Pp n/a-n/a (2023)
Abstract Osteoporosis and cardiovascular disease are common in older adults. Treatment of osteoporosis reduces the burden of debilitating fractures; however, it is important to understand the benefit versus risk of treatment. This study evaluates the
Externí odkaz:
https://doaj.org/article/129cec94551548f8a9a3a4343cd3a9c5
Autor:
Manju Chandran
Publikováno v:
Archives of Endocrinology and Metabolism, Vol 66, Iss 5, Pp 724-738 (2022)
ABSTRACT It is now well recognized that over the lifetime of a patient with osteoporosis, more than one medication will be needed to treat the disease and to decrease fracture risk. Though current gaps in osteoporosis therapy can be potentially mitig
Externí odkaz:
https://doaj.org/article/92053bb634714132a37219127ca49a7f
Autor:
Takumi Kaku, Yoto Oh, Shingo Sato, Hirotaka Koyanagi, Yuki Funauchi, Takashi Hirai, Masato Yuasa, Yu Matsukura, Toshitaka Yoshii, Tsuyoshi Nakagawa, Satoshi Miyake, Atsushi Okawa
Publikováno v:
JBMR Plus, Vol 7, Iss 7, Pp n/a-n/a (2023)
ABSTRACT Patients on bone‐modifying agents (BMAs) for bone metastases are at risk of atypical femoral fractures (AFFs), which can lead to a sudden deterioration in performance status. In this study, we sought to determine the prevalence of radiogra
Externí odkaz:
https://doaj.org/article/e57212bf61924c1f8a0e496d8e4c4ba9
Publikováno v:
JBMR Plus, Vol 7, Iss 6, Pp n/a-n/a (2023)
ABSTRACT Most women do not qualify for pharmacologic osteoporosis treatment until more than a decade after menopause, by which time they will have lost up to 30% of their bone mass and may have already sustained fractures. Short or intermittent cours
Externí odkaz:
https://doaj.org/article/bdc411c942ad4703863acef632b6ef75
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
NIHR Open Research, Vol 2 (2022)
Background: Recent studies show that adults with intellectual disabilities (ID) have high incidence of major osteoporotic fracture, especially hip fracture. In those ≥ 50 years, women and men with ID have an approximately two and four times higher
Externí odkaz:
https://doaj.org/article/4c1946d52c5d431ea10441e7bf925e04